From the lab bench to the cloud, Penn Medicine is at the forefront of biomedical discovery—translating research into real-world impact. Explore the latest breakthroughs.
In a historic medical breakthrough, a child with a rare genetic disorder has been successfully treated with a customized CRISPR gene editing therapy.
Penn Medicine research is bringing the “sleeper” phase of cancer to light—creating hope that more cancers could be wiped out for good and never come back.
The Translational Research Immersion Program teaches students to use art to better communicate their research to the public.
The ability of a newly understood stem cell originating in skeletal muscle, Prg4+, to turn into bone could hold the key to bone healing after catastrophic fractures.
Penn research suggests that the Food and Drug Administration should consider approving more and smaller IUDs, such as a variety only available elsewhere.
Penn Medicine and Wharton researchers partner to create CellSpectra and SISKA, offering clues to better treatments for kidney disease and beyond.
A new Penn Medicine study reveals how to reduce harmful inflammation caused by lipid nanoparticles.
Public investments in biomedical research have an outsized effect, driving new scientific insights, economic growth, and ultimately treatments and cures.
The successes of CAR T research show the importance of the cycle of science—sparking new ideas and clinical trials that give patients better options.
The Penn Medicine Co-Investment program spurs faculty innovation, creates jobs, and helps scale up ideas into large-scale clinical studies.
Blocking a single protein can flip tumor-associated macrophages from protecting tumors to attacking them, and Penn Medicine researchers believe they figured out how to trigger the switch. | July 08, 2025
A new “disease-on-a-chip” model developed by a Penn Medicine team can quickly assess new CAR T cell therapies through its recreation of the bone marrow environment in leukemias. | July 01, 2025
Virus-delivered “micro-RNAs” at Penn Medicine blocked a stress granule protein from forming in the brain, slowing disease progression—and increasing survival—in ALS mouse models. | June 25, 2025
Clinical research professionals’ quiet work with patients and data behind the scenes is vital to moving innovative research forward.
A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer.
Carl June, MD, explains how CAR T cell therapy, which has been transformative for blood cancers, holds the potential to help millions more patients.
Bilateral hand transplant at Penn Medicine gives Swiss man new hands 16 years after childhood amputations.
Uterus transplant is still a rare procedure—but for the six moms who have had eight babies to date through Penn’s program, it means the world.
In a proof of concept for a future bridge to transplant, researchers circulated a deceased donor’s blood through a genetically engineered pig liver.
Penn researchers designed an organ-specific mRNA and lipid nanoparticle therapy which could lead to new targeted treatments for damaged organs.
Could the mRNA technology behind COVID vaccines be used to tamp down the immune system for celiac and other autoimmune diseases?
Biomedical innovations using mRNA could prevent, treat, or cure numerous diseases. Penn Medicine is advancing its Nobel Prize-winning technology worldwide.
The Basser Center for BRCA is running an innovative cancer interception clinical trial that depends on volunteers with deep, personal ties to cancer.
Penn Medicine researchers are at the forefront of new scientific efforts to interrupt the development of cancer at its earliest stages.
The gift from Penn alumni Mindy and Jon Gray establishes the Basser Cancer Interception Institute to stop hereditary cancers at the earliest stages.
Subscribe to Penn Medicine newsletters and publications for the latest developments.
